Health Care Activity
CDC Advisors Shift COVID-19 Vaccine Guidance to Individual Decision-Making
CDC; COVID-19 vaccine; vaccine recommendation; individual choice; ACIP; provider consultation
FDA Scrutinizes Telehealth Firms Like Hims for GLP-1 Drug Advertising Practices
FDA; Hims; telehealth; GLP-1; advertising; weight-loss drugs; compound drugs; Super Bowl ad; misleading claims
Trump Administration May Exempt Some Pharma Products from Future Tariffs in Trade Policy Shift
pharmaceutical tariffs; tariff exemptions; Trump administration; Section 232 investigation; trade policy; reciprocal tariffs; generic pharmaceuticals; active pharmaceutical ingredients; commerce secretary authority
Takeda’s Phase 3 Success Positions Oveporexton (TAK-861) as Potential First Mover in Multibillion-Dollar Narcolepsy Market
Takeda; Phase 3; narcolepsy type 1; oveporexton; TAK-861; orexin agonist; multibillion-dollar market; clinical trial results; first mover; standard of care
Recent Developments in Logistical Coordination for Decentralized Clinical Trials (DCTs)
Decentralized Clinical Trials; Logistics; FDA Guidance 2024; Remote Patient Monitoring; Supply Chain Management; Digital Trial Platforms
Indivior Initiates Cost-Cutting Plan with Job Cuts and Real-Estate Review
Indivior; job cuts; real-estate; cost-cutting; restructuring; sales guidance; profit guidance; Opvee divestiture; competition; generic drugs
Who Is Making AI Work in Drug R&D in 2025?
AI drug discovery; Big Pharma; biopharma startups; clinical trials; FDA guidance; personalized medicine; drug development efficiency
FDA Suspends Valneva’s Chikungunya Vaccine, Ixchiq, Due to Serious Safety Concerns
FDA; Valneva; Ixchiq; chikungunya vaccine; license suspension; safety; serious adverse events; encephalitis; hospitalizations; deaths
UK Drugmakers and Government at Impasse Over New Medicine Rebate Scheme
UK; drugmakers; medicine rebate; government negotiations; VPAG; statutory scheme; pharmaceutical industry; National Health Service; rebate rates
Trump Locks in 15% Pharmaceutical Tariff Rate for EU, Generic Drugs Exempted
15% tariff; pharmaceuticals; EU; Trump administration; generic drugs; trade deal; tariff exemption; brand-name drugs; transatlantic trade; Section 232 investigation